HER-2 PROTEIN OVEREXPRESSION
Clinical trials for HER-2 PROTEIN OVEREXPRESSION explained in plain language.
Never miss a new study
Get alerted when new HER-2 PROTEIN OVEREXPRESSION trials appear
Sign up with your email to follow new studies for HER-2 PROTEIN OVEREXPRESSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for hard-to-treat HER2 cancers: zanidatamab enters phase 2 trial
Disease control Recruiting nowThis study tests a drug called zanidatamab in about 200 adults with several types of advanced solid tumors (like breast, lung, or stomach cancer) that have high levels of HER2 protein and have worsened after at least one prior treatment. The goal is to see if zanidatamab can shri…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase: PHASE2 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC
-
Engineered immune cells join forces with checkpoint drugs to fight sarcoma
Disease control Recruiting nowThis early-stage study tests whether giving HER2-targeting CAR T cells along with an immune checkpoint inhibitor (pembrolizumab or nivolumab) is safe for people with advanced sarcoma. About 25 participants will receive chemotherapy to prepare their bodies, then the CAR T cells, f…
Matched conditions: HER-2 PROTEIN OVEREXPRESSION
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 11, 2026 12:10 UTC